This is a working overview of bioregulator, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-23 and is reviewed periodically as new material appears.
Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
The proposed relationship between epitalon and pineal function is a central part of its background. Khavinson's group reported that short peptides corresponding to regions of larger pineal proteins could influence gene expression in cells. Epitalon was framed as a synthetic analogue of an active fragment rather than a direct isolation product. Whether the tetrapeptide reproduces the effects of the parent extract is an open question, because comparative studies are limited and the parent extract itself is not a single defined substance.
Interest in epitalon is usually discussed within the broader field of short peptide bioregulators, a category that includes other synthetic di-, tri-, and tetrapeptides studied by the same research group. These compounds share a common rationale: that small fragments of tissue-derived proteins can retain biological activity and can be produced reproducibly. The category as a whole remains outside mainstream pharmacological consensus, and epitalon specifically has a limited presence in independent, non-Russian research literature, which shapes how its evidence base is described.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic tetrapeptide | Four amino acid residues |
| Residue sequence | Ala-Glu-Asp-Gly | Abbreviated AEDG |
| Approximate mass | 390.35 Da | Monoisotopic, free base form |
| Parent preparation | Epithalamin extract | Derived from pineal tissue |
| Common spelling variants | Epithalon, epithalone, AEDG | Affects literature retrieval |
Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.
Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.
The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.
Published evidence comes mainly from Russian-language journals and from a single research group, with small sample sizes and limited independent replication. A few laboratories outside that group have examined related peptides and reported weaker or absent telomerase effects, so the central claim is best described as contested rather than settled. Rodent studies report modest changes in some ageing markers and in survival, but designs vary and control conditions are often sparse. No large randomised trial in humans has been published, and long-term safety data in healthy populations are correspondingly thin.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. It was designed at the St. Petersburg Institute of Bioregulation and Gerontology as a short, chemically defined analogue of epithalamin, a fraction obtained from bovine pineal tissue. Small peptide bioregulators of this type formed a long-running line of work there from the 1980s onward. Because the molecule is produced by solid-phase synthesis rather than extraction, its composition is exact and its purity can be measured directly.
He then phoned Bouthaina Shaaban, asking her to write a speech for him, and told his presidential office that he was driving home for the night. In truth, Assad left for an airport, secretly boarded an airplane which then flew under the radar with the aircraft's transponder switched off to Khmeimim Air Base from where he fled to Russia. He informed none of his inner circle members or even close family members of his flight, with even his brother Maher al-Assad being left behind. The Telegram account of the Syrian presidency would later publish a statement attributed to Assad, saying that he had gone to a Russian military base in Latakia Governorate "to oversee combat operations" following the fall of Damascus, but was evacuated out of the country by Russia after coming under siege from rebel forces, adding that he had no intention of resigning or going into exile. After the president had disappeared, his media director Kamel Sakr initially told journalists that Assad was going to "deliver a statement very soon". Not long after, he stopped responding to calls, as did Minister of the Interior Mohammad Khaled al-Rahmoun. Government loyalists realized that Assad had fled upon learning that his home was deserted, with the Republican Guard also no longer deployed at his usual residence. As word of his escape spread, the remaining loyalist resistance completely collapsed. During the night, rebels announced that a "group" of senior government officials and military officers in Damascus were preparing to defect to the opposition.
== Advantage and limitations == Immunoliposomes have many possible applications as described above and have certain advantages in new research and ideas. Some advantages being researched include immunoliposomes targeting specific molecules in the body. In preclinical testing, they can be environmentally responsive to specific conditions of temperature, pH, enzymes, redox reactions, magnetic energy, and light to release drugs. This conditional ability allows immunoliposomes to focus on specific target areas which can be beneficial for drug delivery. Increased targeting allows the possibility for decreased systemic toxicity while increasing drug concentration at a certain site. Even with this advantage of immunoliposomes, there are some challenges in their application. The success of immunoliposomes during in vivo testing has been shown by multiple groups including Meeroekyai et al 2023 and animal testing has been successful in groups such as Refaat et al 2022. However, they struggle to thrive in higher level and clinical testing. This challenge stems from the variability and lack of understanding of tumors, pharmacokinetics, and large scale production of immunoliposomes. For example, tumors vary but typically have increased vascular permeability and decreased lymphatic drainage which lead to the EPR effect. EFR is the enhanced permeability and retention effect in which drug carriers depend on but the effect and environment can vary in solid tumors. This varying environment makes it hard to predict how the immunoliposome acts and quantify its pharmacokinetics.
=== Acidity === The C9–H sites of the fluorene ring are weakly acidic (pKa = 22.6 in DMSO). Deprotonation gives the stable fluorenyl anion, nominally C13H−9, which is aromatic and has an intense orange colour. The anion is a nucleophile. Electrophiles react with it by adding to the 9-position. The purification of fluorene exploits its acidity and the low solubility of its sodium derivative in hydrocarbon solvents. Both protons can be removed from C9. For example, 9,9-fluorenyldipotassium can be obtained by treating fluorene with potassium metal in boiling dioxane.
=== Inner systematics === A 2011 study supported separating megabats and microbats. However, other and more recent evidence indicates that megabats belong within the microbats. Two new suborders have been proposed; Yinpterochiroptera includes the Pteropodidae, or megabat family, as well as the families Rhinolophidae, Hipposideridae, Craseonycteridae, Megadermatidae, and Rhinopomatidae. Yangochiroptera includes the other families of bats (all of which use laryngeal echolocation), a conclusion supported by a 2005 DNA study. A 2013 phylogenomic study supported the two new proposed suborders.
Sources: en.wikipedia.org
=== Initial studies === Due to the remarkable rubber elasticity of resilin, scientists began exploring recombinant versions for a variety of material and medical applications. With the rise in DNA technologies, this field of research has seen a rapid increase in the synthesis of biosynthetic protein polymers that can be tuned to having certain mechanical properties. Thus, this field of research is rather promising and can provide new methods for treating diseases and disorders that affect the population. Recombinant resilin was first studied in 2005 when it was expressed in Escherichia coli from the first exon of the Drosophila melanogaster's CG15920 gene. During its study, pure resilin was synthesized into 20% protein-mass hydrogel and was cross-linked with ruthenium-catalyzed tyrosine in the presence of ultraviolet light. This reaction yielded the product, recombinant resilin (rec1-Resilin). One of the most important aspects of successful rec1-Resilin synthesis is that its mechanical properties match that of the original resilin (native resilin). In the study indicated above, scanning probe microscopy (SPM) and atomic-force microscopy (AFM) were used to investigate the mechanical properties of rec1-Resilin and native resilin. The results of these tests revealed that the resilience of both recombinant and native resilin were relatively similar but can differ in its applications. In this study, rec1-Resilin could be placed into a polymeric scaffold to mimic the extracellular matrix in order to generate a cell and tissue responses.
== Adverse effects == In the treatment of psoriasis, the most common adverse events are gastrointestinal events, flushing and lymphopenia, which are usually mild. Other adverse events include progressive multifocal leukoencephalopathy (PML) and Fanconi syndrome, which are considered rare. PML is probably caused by a combination of factors. A previous infection with the John-Cunningham virus (JCV) is considered a prerequisite for the development of PML. In a PML review, all confirmed cases were of patients exposed to periods of varying lymphopenia. For multiple sclerosis, adverse effects include flushing and gastrointestinal events, such as diarrhoea, nausea and upper abdominal pain. The drug label includes warnings about the risk of anaphylaxis and angioedema, PML, lymphopenia and liver damage. There is no information on how dimethyl fumarate affects the fetus during pregnancy; in animal tests there was fetal harm at clinically relevant doses.
== Endocrine system == Adrenocortical adenoma Adrenocortical carcinoma Carcinoid Gastrinoma Glucagonoma Insulinoma Islet cell carcinoma (endocrine pancreas) Merkel cell carcinoma Multiple endocrine neoplasia syndrome Pancreatic cancer Parathyroid cancer Pheochromocytoma Somatostatinoma Thyroid cancer VIPoma
Premier League: 1997–98, 2001–02, 2003–04 FA Cup: 1997–98, 2001–02, 2002–03, 2004–05, 2013–14, 2014–15, 2016–17; runner-up: 2000–01 FA Charity/Community Shield: 1998, 1999, 2002, 2004, 2014, 2015 2017 Football League/EFL Cup runner-up: 2006–07, 2010–11, 2017–18 UEFA Champions League runner-up: 2005–06 UEFA Cup runner-up: 1999–2000 Individual
When Eddy first met Quimby in Portland in October 1862, she had to be helped up the stairs to his consulting rooms. She spoke highly of him the following month in a letter to the Portland Evening Courier: "This truth which he opposes to the error of giving intelligence to matter and placing pain where it never placed itself ... changes the currents of the system to their normal action ..." In a second letter she offered to supply quotations from Quimby's "theory of Christ (not Jesus)." Between then and May 1864, Eddy returned to see Quimby several times, staying for weeks in Portland and visiting him daily. She wrote to him regularly, and composed a sonnet for him, "Mid light of science sits the sage profound." Eddy first used mental healing on a patient in March 1864, when one of Quimby's patients in Portland, Mary Ann Jarvis, suffered a relapse when she returned home to Warren, Maine. Eddy stayed with her for two months, giving Jarvis mental healing to ease a breathing problem, and writing to Quimby six times for absent treatment for herself. She called the latter "angel visits"; in one of her letters to Quimby, she said that she had seen him in her room. In April she gave a public lecture in Warren, contrasting mental healing with Spiritualism, entitled: "P. P. Quimby's Spiritual Science healing disease, as opposed to Deism or Rochester Rapping Spiritualism."
Sources: en.wikipedia.org
== Herbalism == A. mongholicus is used in traditional Chinese medicine (TCM). A. mongholicus is a component in Lectranal, a food supplement used in treatment of seasonal allergic rhinitis, though there is limited evidence of its effectiveness.
== Use and effects == In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists 2C-B's dose range as 12 to 24 mg orally and its duration as 4 to 8 hours. However, in an earlier report, he described an effective dose range of 8 to 10 mg orally and a duration of 6 to 8 hours. Threshold effects occur at a dose of 4 mg orally. A wider recreational dose range of 2 to 55 mg or more orally has been described as well, with a typical dose estimate of about 20 mg. A low dose has been said to be 5 to 15 mg, a moderate dose 10 to 25 mg, and a high or strong dose 20 to 50 mg. Most people use doses of 20 mg or lower. Shulgin and others describe 2C-B as having a steep dose–response curve, such that a small increase in dose can result in an unexpectedly large increase in effects. Over the 12 to 24 mg dose range, every 2 mg increment can result in a profound increase or change in effects. Higher doses are said to lead to more intense but not longer-lasting effects. The drug's onset is about 0.5 to 1.2 hours, with a range of 0.3 to 1.5 hours, and its time to peak effects is about 2.5 hours on average. Effects last about 3.1 to 4.9 hours on average and are shorter than those of psilocybin. In addition to oral administration, 2C-B may be insufflated less commonly, with doses being approximately one-third of those of the oral route or in the range of 10 to 30 mg and with this route producing more rapid and intense effects.
Polycondensation involves the formation of polymers through condensation reactions between different species, creating condensation polymers. With automated synthesis, General electric manufactured an approach for melt-polymerizations of BPA and diphenyl carbonate (DPC), using sodium hydroxide (NaOH) as the catalyst. Once the results were analyzed, it was shown that, by using an automated method of polymerization, the effect of varying the catalyst amount became more distinct and improved the reproducibility for the reaction. Furthermore, it demonstrated an increase within the homogeneity of the polymers in the microreactors.
=== RTG (radioisotope thermoelectric generator) power generation === As 241Am has a roughly similar half-life to 238Pu (432.6 years Am-241, 87.7 years Pu-238, decay energies nearly the same), it has been proposed as an active isotope of radioisotope thermoelectric generators, for use in spacecraft. Even though americium-241 produces less heat and electricity than plutonium-238 (the power yield is 114.7 milliwatts per gram [3.25 watts per ounce] for 241Am vs. 570 mW/g [16 W/oz] for 238Pu) and its radiation poses a greater threat to humans owing to gamma emission, it has advantages for long duration missions with its significantly longer half-life. The European Space Agency is working on RTGs based on americium-241 for its space probes as a result of the global shortage of plutonium-238 and easy access to americium-241 in Europe from nuclear waste reprocessing. Its shielding requirements in an RTG are the second lowest of all possible isotopes: only 238Pu requires less. An advantage over 238Pu is that it is produced as nuclear waste already. Prototype designs of 241Am RTGs expect 2–2.2 We/kg for a 5–50 We design, putting 241Am RTGs at parity with 238Pu RTGs within that power range, as the vast majority of the mass of an RTG is not the radioisotope, but the thermoelectrics, radiators, and isotope containment mass.
This allows the creation of a novel formulation that retains the smooth control of a long-acting basal with rapid-acting mealtime control from insulin aspart. This 2-component insulin retains the ultralow risk characteristics of degludec with simultaneous mealtime coverage.
Sources: en.wikipedia.org
It is based on epithalamin, a peptide-rich preparation obtained from pineal gland tissue and studied in the former Soviet Union. Researchers later identified the tetrapeptide AEDG as a constituent fragment of that material. Modern supplies are produced by chemical synthesis rather than tissue extraction.
No. Epithalamin is a heterogeneous extract containing many peptides, while epitalon is a single synthesised tetrapeptide. Publications sometimes treat findings from the two as equivalent, which is a common source of confusion. Their compositions differ and they are not interchangeable in analytical terms.
Most published work uses cell cultures or rodents because those models are faster and less costly to run. The few human trials that have been reported are small, and several lack control groups or blinding. This restricts what can reasonably be concluded about effects in people.
Epitalon is a synthetic tetrapeptide composed of four amino acids: alanine, glutamate, aspartate, and glycine. It is written as Ala-Glu-Asp-Gly. The free peptide has a molecular weight of about 390 daltons and is normally supplied as a lyophilized powder.